230 related articles for article (PubMed ID: 38660139)
1. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Parrondo RD; Ailawadhi S; Cerchione C
Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
[TBL] [Abstract][Full Text] [Related]
2. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
Landgren O; Nadeem O
Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
[TBL] [Abstract][Full Text] [Related]
3. Bispecific antibodies in multiple myeloma treatment: A journey in progress.
Cho SF; Yeh TJ; Anderson KC; Tai YT
Front Oncol; 2022; 12():1032775. PubMed ID: 36330495
[TBL] [Abstract][Full Text] [Related]
4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
5. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
6. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
Costa LJ; Rodriguez-Otero P
Adv Ther; 2024 Apr; ():. PubMed ID: 38642197
[TBL] [Abstract][Full Text] [Related]
7. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
Granger K; Gaffney KJ; Davis JA
J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Xia J; Li Z; Xu K
J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
10. Recent advances and future perspectives of T-cell engagers in lymphoid malignancies.
Shirouchi Y; Maruyama D
Jpn J Clin Oncol; 2024 Apr; 54(4):376-385. PubMed ID: 38183209
[TBL] [Abstract][Full Text] [Related]
11. Antibodies and bispecifics for multiple myeloma: effective effector therapy.
Cipkar C; Chen C; Trudel S
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):163-172. PubMed ID: 36485135
[TBL] [Abstract][Full Text] [Related]
12. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
[TBL] [Abstract][Full Text] [Related]
13. Bispecific T-cell engagers for treatment of multiple myeloma.
Ravi G; Costa LJ
Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
[TBL] [Abstract][Full Text] [Related]
14. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
Cho SF; Xing L; Anderson KC; Tai YT
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885245
[TBL] [Abstract][Full Text] [Related]
15. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A
Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865
[TBL] [Abstract][Full Text] [Related]
16. Cellular therapy for multiple myeloma: what's now and what's next.
Rodriguez-Otero P; San-Miguel JF
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):180-189. PubMed ID: 36485132
[TBL] [Abstract][Full Text] [Related]
17. T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA.
van de Donk NWCJ; O'Neill C; de Ruijter MEM; Verkleij CPM; Zweegman S
Curr Opin Oncol; 2023 Nov; 35(6):601-611. PubMed ID: 37501530
[TBL] [Abstract][Full Text] [Related]
18. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
19. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
Reynolds G; Cliff ERS; Mohyuddin GR; Popat R; Midha S; Liet Hing MN; Harrison SJ; Kesselheim AS; Teh BW
Blood Adv; 2023 Oct; 7(19):5898-5903. PubMed ID: 37467036
[TBL] [Abstract][Full Text] [Related]
20. BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms.
Lee H; Neri P; Bahlis NJ
Blood; 2024 Mar; 143(13):1211-1217. PubMed ID: 38194680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
